Abstract
In a four-week double-blind trial of 62 patients with Parkinsonism 29 were treated withamantadine and 33 with a placebo. Modest but statistically significant improvement was observed in the first group, optimum benefit occurring after the first two weeks. Patients' reactions to the drug were favourable in 79%, and side effects were insignificant. Though amantadine appears to be a useful additive drug in the treatment of Parkinsonism, its value as a single treatment is as yet undetermined.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Alstead S. Drug therapy in parkinsonism. Lancet. 1970 Mar 7;1(7645):522–522. doi: 10.1016/s0140-6736(70)91607-7. [DOI] [PubMed] [Google Scholar]
- Calne D. B., Brennan J., Spiers A. S., Stern G. M. Hypotension caused by L-dopa. Br Med J. 1970 Feb 21;1(5694):474–475. doi: 10.1136/bmj.1.5694.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Amantadine in parkinsonism. Lancet. 1970 May 30;1(7657):1127–1129. doi: 10.1016/s0140-6736(70)91210-9. [DOI] [PubMed] [Google Scholar]
- Parkes J. D., Calver D. M., Zilkha K. J., Knill-Jones R. P. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet. 1970 Feb 7;1(7641):259–262. doi: 10.1016/s0140-6736(70)90634-3. [DOI] [PubMed] [Google Scholar]
- Parkes J. D., Zilkha K. J., Marsden P., Baxter R. C., Knill-Jones R. P. Amantadine dosage in treatment of Parkinson's disease. Lancet. 1970 May 30;1(7657):1130–1133. doi: 10.1016/s0140-6736(70)91211-0. [DOI] [PubMed] [Google Scholar]
- Schwab R. S., England A. C., Jr, Poskanzer D. C., Young R. R. Amantadine in the treatment of Parkinson's disease. JAMA. 1969 May 19;208(7):1168–1170. [PubMed] [Google Scholar]